The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling ...

Olema Pharmaceuticals Inc (OLMA) stock saw a modest uptick, ending the day at $5.83 which represents a slight increase of $0.22 or 3.92% from the prior close of $5.61. The stock opened at $5.61 and ...

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Janus Henderson Group PLC trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 68.2% ...

Geode Capital Management LLC reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% ...

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Olema Pharmaceuticals ( (OLMA)) has provided an update. Olema Pharmaceuticals has announced FDA clearance for ...

Olema Oncology SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused ...

Olema Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 14, 2025, discussing its breast cancer therapies. Olema Pharmaceuticals, Inc., a clinical-stage ...